Therapeutic strategy targeting NFκB-IL6 pathway against progression and paraneoplastic syndrome in prostate cancer

本研究旨在阐明NF - κB- il6通路的病理生理作用及NF - κB抑制剂DHMEQ在前列腺癌中的抗肿瘤作用。DHMEQ对前列腺癌细胞呈剂量依赖性和时间依赖性的细胞毒作用，显著增加细胞周期中G2/M阻滞，增强多西紫杉醇对前列腺癌细胞的细胞毒作用。DHMEQ可显著增强放疗对前列腺癌的细胞毒作用，可能是通过抑制放疗引起的nf - κ b活性升高，提高细胞中G2/M阻滞的比例。抑制NFκB活性可能成为治疗前列腺癌的一种新的治疗方式。

This study was undertaken to elucidate the pathophysiological role of NFκB－IL6 pathway and antitumor effects of NF κB inhibitors including dihydroxymethylepoxyquinomicin (DHMEQ) in prostate cancer. DHMEQ showed significant cytotoxic effects on prostate cancer cells in dose dependent and time dependent manners, produced a significant increase in G2/M arrest in the cell cycle and enhanced the cytotoxic effects of docetaxel on prostatecancer cells. DHMEQ significantly enhanced cytotoxic effects of radiation on prostate cancer, presumably through inhibiting the increased NFκB activity induced by radiation and enhancing the proportion of G2/M arrest in the cells in combination with radiation. Inhibition of NFκB activity may become a new therapeutic modality for treating prostate cancer.